Feature|Videos|July 23, 2025
Rethinking Go-to-Market Strategy with Innovation in a Patient-Centric Era
A panel of industry leaders share key insights supporting the integration of patient-centric strategies into current and future drug development and market access efforts.
Advertisement
Episodes in this series
As the series closes, the panel reflects on an often underrepresented but crucial stakeholder: the patient. The discussion underscores the need for a more patient-centered market access strategy—one that incorporates health equity, diagnostic and treatment journey support, and clearer communication around cost and adherence.
Key discussion topics include:
- How social determinants of health (SDOH) shape real-world treatment access.
- The growing need for payer transparency and patient trust in the marketplace.
- Strategies to engage patients early in development to ensure success.
Advertisement
Related to this article
Nuvera’s PURE Engagement research, built on feedback from more than 2,300 physicians and support staff, ranks 2026 patient support leaders by company size and therapeutic area.
Specialty distribution and provider platforms drove September-quarter profit gains at the Big Three as brand pricing weighed on results.
Siloed pricing, contracting and affordability decisions can undercut a launch. IQVIA experts explain how system-level modeling surfaces trade-offs early.
In this week’s Pharma Pulse, CVS Health plans to separate into two public companies, Bayer weighs what MFN pricing could mean for its launch strategies and an ACTO survey finds most life sciences leaders see no clear industry standard for responsible AI.
Accessia Health’s Tiara Green says Part D reforms eased drug costs, but premiums, deductibles and payer policies still limit patient access.
ELPRO CEO Frederik Dresen explains how cold chain monitoring moved from compliance to risk management, and what biologics and advanced therapies demand.
Inizio Ignite leaders argue static, milestone-driven launch plans fall short and AI sharpens execution only when built on a sound strategy.
Foreign-trade zones allow pharma companies to hold imported inventory closer to U.S. demand while deferring duties and keeping market allocation open.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Pharma Pulse: CVS Health to Break in Two, Bayer Weighs MFN
2
2026 Brought Progress on Drug Prices. What Will It Take to Improve Patient Access in 2027?
3
Big Three Distributors Lean on Specialty for Profit Growth
4
The System-Level View That Sound Market Access Decisions Are Missing
5